🇺🇸 FDA
Pipeline program

rapcabtagene autoleucel

CYTB323K12201

Phase 2 mab active

Quick answer

rapcabtagene autoleucel for Scleroderma, Diffuse is a Phase 2 program (mab) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Scleroderma, Diffuse
Phase
Phase 2
Modality
mab
Status
active

Clinical trials